v
Search
Advanced

Publications > Journals > Future Integrative Medicine> Article Full Text

  • Original Article
  • OPEN ACCESS

Exploring the Modern Pharmacological Mechanism of Special Ingredients of Panax Ginseng for Ulcerative Colitis based on Network Pharmacology

  • Weichen Si* 
 Author information 

Abstract

Background and Objective

To explore the main action targets and key pathways, along with their mechanisms of action, of Panax ginseng’s special ingredients in the treatment of ulcerative colitis using network pharmacology methods. To provide a theoretical basis for subsequent laboratory experiments and clinical trials.

Methods

The main active ingredients of Panax notoginseng were obtained through the TCMSP database and the specific ingredients were screened. The targets of Panax notoginseng-specific components were obtained from the Swiss Target Prediction database. The GeneCards, OMIM, and DisGent databases were used to obtain the targets related to ulcerative colitis. The protein interaction network (PPI) of intersecting targets was constructed using the STRING database. GO function and KEGG pathway enrichment analysis were performed in R language software. Construction of the herb-component-target-disease-KEGG pathway network was achieved using Cytoscape software.

Results

Seven major active ingredients of Panax notoginseng were obtained, and ginsenoside f2 was found to be a special ingredient, corresponding to 16 potential targets. A search of the disease database yielded 5,536 targets for ulcerative colitis. Eight core targets were obtained by protein interaction analysis of the intersecting targets: STAT3, VEGFA, HSP90AA1, FGF2, IL2, MET, BCL2L1, and RORC, respectively. 417 entries were obtained by GO functional enrichment analysis, and 22 statistically significant pathways were obtained by KEGG enrichment analysis.

Conclusion

The mechanism of action of ginsenoside f2 in the treatment of ulcerative colitis features multi-target and multi-pathway interactions. The receptors may be related to STAT3, VEGFA, HSP90AA1, FGF2, IL2, MET, and other targets, and the main signaling pathways may be related to the PI3K-Akt signaling pathway, Th17 cell differentiation, and inflammatory bowel disease among others and this provides a theoretical basis for the next in-depth experimental study.

Keywords

Bioinformatics, Panax ginseng, Ulcerative colitis, Signaling pathway

Introduction

Ulcerative colitis (UC) is a chronic digestive system disorder characterized by abnormal inflammation in the rectum and colon, resulting in the formation of ulcers. It usually emerges between the ages of 15 and 30 but can occur at any age,1 and is associated with recurring flare-ups throughout one’s life, accompanied by various symptoms. Common symptoms include abdominal pain, cramps, frequent diarrhea (often with blood, pus, or mucus in the stools),2 nausea, loss of appetite, fatigue, and fever. Chronic bleeding from the inflamed bowel may lead to anemia,3 while difficulties in nutrient absorption often cause weight loss. In children affected by UC, growth may be slower than average.4 Although less common, UC can also affect other parts of the body such as the skin, joints, eyes, kidneys, or liver due to abnormal inflammation. Toxic megacolon, a rare and life-threatening complication, involves an enlarged colon and severe bacterial infections (sepsis). Moreover, individuals with UC have an increased risk of developing bowel cancer, particularly if the entire colon is inflamed or if the condition persists for more than eight years.5,6 Ulcerative colitis falls under the broader category of inflammatory bowel diseases (IBD), alongside Crohn’s disease. While UC primarily affects the colon’s lining, Crohn’s disease can cause inflammation in any part of the digestive system, involving deeper layers of the bowel tissue.7

Currently, there are no targeted drugs for ulcerative colitis. The treatment of UC in China comprises mainly Western medicine, supplemented by traditional Chinese medicine (TCM). There are, however, problems with Western medicine in the treatment of ulcerative colitis such as a high recurrence rate, many adverse reactions, and unsatisfactory efficacy in some refractory patients. For mild to moderate ulcerative colitis, traditional Chinese medicine can significantly improve the clinical symptoms, and even play a role in the maintenance of the remission phase of Western medicine. Ulcerative colitis belongs to the category of “dysentery” in traditional Chinese medicine. It is based on the weakness of the spleen and stomach and is related to the causes of an unclean diet, emotional disorders, and the feeling of external evil.8 Based on previous studies, we believe that stasis is involved in the process of onset and in each syndrome type. As such, syndrome differentiation treatment combined with the treatment of traditional Chinese medicine for removing blood stasis has a good clinical effect.Panax notoginseng,9 which can be used to stop bleeding from dysentery and relieve intestinal stasis, is the main blood-activating drug in the prescription. Pharmacological studies have shown that Panax notoginseng can activate blood circulation and has hemostatic, anti-inflammatory, and immune regulation qualities.10 Therefore, in this study, network pharmacology was used to analyze the effective components of Panax notoginseng in treating ulcerative colitis at the molecular level and to predict its target and signal pathway, providing ideas and a basis for clinical and experimental research.

Research methods

Screening of active ingredients and targets of Panax notoginseng

Panax notoginseng was input into the TCMSP platform (https://tcmsp-e.com/ )11 with the keyword “Panax notoginseng”, and the effective ingredients were screened with drug class (DL) ≥0.18 and oral benefit (OB) ≥30% as the conditions. In addition, the relevant Chinese medicines made from the effective ingredients of Panax notoginseng were searched on the TCMSP platform, and the ingredients with the least associated Chinese medicines were selected as the special components. The special composition and structural information of notoginseng was retrieved from the PubChem database (https://pubchem.ncbi.nlm.nih.gov/ ).12 The structural information was retrieved from the Swiss Target Prediction database (http://www.swisstargetprediction.ch/ )13 to ascertain the related targets. The target was screened with “Probability > 0” as the screening condition.

Acquisition of disease targets

The search terms “Ulcerative Colitis” and “human” were used as the retrieval objects to obtain disease targets through the Genecards database (https://www.genecards.org/ ),14 OMIM database (https://www.omim.org/ ),15 and DisGeNET database (https://www.disgenet.org ).16

Acquisition of intersection targets

Application Venny (https://bioinfogp.cnb.csic.es/tools/venny/ )17 software was used to ascertain notoginseng special ingredients targets and disease intersection targets, as notoginseng special components in the treatment of Ulcerative Colitis of potential targets.

Protein interaction network (PPI) construction and network topology analysis

Using the String (https://string-db.org/ ) platform,18 the intersection target was imported, the object was set as “homo sapiens”, the highest confidence was 0.900, and the free gene nodes were hidden to obtain the protein interaction relationship. The results were imported into Cytoscape (3.9.1) software and a network analyzer was selected to obtain network topology parameters. The degrees, betweenness centrality, and closeness centrality of the PPI network nodes were analyzed and calculated.

GO and KEGG enrichment analysis

Bioinformatics open-source software was used to install and run clusterProfiler,19 DOSE,20 and Pathview21 packages in R language software (3.5.1) for the GO and KEGG enrichment analysis. Visual display was achieved through the microscopic letter platform (https://www.bioinformatics.com.cn/ ). The GO enrichment analysis annotated Panax notoginseng therapy ulcerative from three aspects: biological process (BP), cellular component (CC), and molecular function (MF) of the target of colitis. The first ten GO items of BP, CC, and MF were screened out according to the P-value size, and the bubble map was drawn. Cnetplot belongs to the Gene-Concept Network, which describes the links between genes and biological pathways as a network. It is possible to intuitively observe the genes involved in these items and the interactive genes between the items. Cnetplot was used to display the interacting genes of the first 10 KEGG pathways. Emapplot shows the overlapping relationship between the enriched pathways.

Drawing the network diagram of the herb-component-target-disease-KEGG pathway

The contents of Panax notoginseng, special components, target sites, and KEGG pathway were collected and imported into Cytoscape software to draw the network diagram of the herb-component-target-disease-KEGG pathway.

Results

Natural drug active ingredients, diseases, and intersection targets

With “Panax notoginseng” as the keyword, 119 Panax notoginseng components were screened on the TCMSP platform, among which 8 components met the screening conditions (OB ≥ 30%, DL ≥ 0.18). Among the eight ingredients, ginsenoside f2 was the least associated with traditional Chinese medicine (Table 1), only Panax notoginseng and gynostaphyllum pentaphyllum. Finally, ginsenoside f2 was determined to be the special component of Panax notoginseng. The screening process is shown in Figure 1. Through the Swiss Target Prediction database retrieval, 16 ginsenoside f2 targets were obtained with “Probability > 0” as the screening condition. By searching GeneCards, OMIM, and DisGENET databases, 5,536 disease targets were obtained after removing duplicates. Venny software was used to take the intersection of TCM targets and disease targets and 12 intersection targets were obtained, which were potential targets of ginsenoside f2 in the treatment of Ulcerative Colitis (Fig. 2). The four targets of PTAFR, GSAP, FGF1 and LGALS8 in ginsenoside f2 were not associated with ulcerative colitis.

Table 1

Quantity of Chinese medicine associated with Panax notoginseng components

Mol IDComponent nameRelated herbs number
MOL001494mandenol35
MOL001792DFV10
MOL002879Diop14
MOL000358beta-sitosterol245
MOL000449stigmasterol133
MOL005344ginsenoside rh25
MOL007475ginsenoside f22
MOL000098quercetin188

DFV, dried fruit vinegar; Diop, diopside; Mol ID, molecule ID.

Flow chart of screening special components of Panax notoginseng.
Fig. 1  Flow chart of screening special components of Panax notoginseng.
(a) Drug target and disease target intersection map; (b) PPI network topology analysis diagram.
Fig. 2  (a) Drug target and disease target intersection map; (b) PPI network topology analysis diagram.

The darker the color and the larger the dot, the larger the degree value.

PPI network construction and network topology analysis

The topology of the PPI network was analyzed using Cytoscape software, which contains 8 nodes and 11 edges (Fig. 2). The targets were STAT3, VEGFA, HSP90AA1, FGF2, IL2, MET, BCL2L1, and RORC, which were sorted by Degree size and listed in the key target information table (Table 2). Among them, the STAT3 target had the highest Degree value of 7.

Table 2

Key target information table

NameDegreeBetweenness CentralityCloseness Centrality
STAT370.7142857141
VEGFA40.0714285710.7
HSP90AA130.0238095240.636363636
FGF2200.583333333
IL2200.583333333
MET200.583333333
BCL2L1100.538461538
RORC100.538461538

GO and KEGG enrichment analysis

The results of the GO enrichment analysis involved a total of 417 statistically significant pathways (p < 0.05) (Fig. 3), among which 365 statistically significant BP entries were involved in positive chemotaxis, positive regulation of endothelial cell chemotaxis, regulation of endothelial cell chemotaxis, T cell activation involved in immune response, etc. And 8 statistically significant CC entries, mainly related to secretory granule lumen, cytoplasmic vesicle lumen, vesicle lumen, lysosomal lumen, etc. And 44 statistically significant MF entries, mainly related to chemoattractant activity, growth factor receptor binding, and protein phosphatase binding, etc. The KEGG enrichment analysis yielded 22 statistically significant pathways, and the top ten KEGG enrichment analyses are shown in Figure 3. The analysis mainly involved EGFR tyrosine kinase inhibitor resistance, PI3K-Akt signaling pathway, proteoglycans in cancer, Th17 cell differentiation, inflammatory bowel disease, etc. The information on the top ten pathways analyzed by KEGG enrichment is shown in Table 3. It shows that ginsenoside f2 can treat ulcerative colitis by acting on different signaling pathways. Cnetplot analysis can visualize the interacting genes between each KEGG pathway (Fig. 4), STAT3, VEGFA, HSP90AA1, FGF2, IL2, MET, BCL2L1, and the Emapplot plot is shown in Figure 5.

(a) Bubble diagram of GO-BP enrichment analysis; (b) Bubble diagram of GO-CC enrichment-analysis bubble map; (c) Bubble diagram of GO-MF enrichment analysis; (d) Bubble map of the top ten channels with KEGG enrichment fraction.
Fig. 3  (a) Bubble diagram of GO-BP enrichment analysis; (b) Bubble diagram of GO-CC enrichment-analysis bubble map; (c) Bubble diagram of GO-MF enrichment analysis; (d) Bubble map of the top ten channels with KEGG enrichment fraction.
Table 3

Data of the top ten pathways of KEGG enrichment

IDDescriptionGeneRatioBgRatioP-valueCount
hsa01521EGFR tyrosine kinase inhibitor resistance5/1079/82231.74788E-085
hsa04151PI3K-Akt signaling pathway6/10354/82231.10709E-066
hsa05205Proteoglycans in cancer5/10205/82232.08813E-065
hsa04659Th17 cell differentiation4/10108/82235.56195E-064
hsa05321Inflammatory bowel disease3/1065/82235.43815E-053
hsa05207Chemical carcinogenesis - receptor activation4/10212/82237.98371E-054
hsa05212Pancreatic cancer3/1076/82238.69082E-053
hsa04014Ras signaling pathway4/10236/82230.0001212224
hsa05162Measles3/10139/82230.0005199833
hsa04630JAK-STAT signaling pathway3/10166/82230.0008734913

BgRatio, Background Ratio.

Cnetplot diagram.
Fig. 4  Cnetplot diagram.
Emapplot diagram.
Fig. 5  Emapplot diagram.

Construction of the network diagram of the herb-component-target-disease-KEGG pathway

The contents of the first 10 KEGG pathways of Panax notoginseng, ginsenoside f2, target, ulcerative colitis, and enrichment fraction were summarized. The above information was mapped into the herb-component-target-disease-KEGG pathway network diagram using Cytoscape software (Fig. 6). The network diagram has 25 nodes and 63 edges.

Network diagram of herb-component-target-disease-KEGG pathway.
Fig. 6  Network diagram of herb-component-target-disease-KEGG pathway.

Green represents traditional Chinese medicine; orange represents a particular active ingredient; pink represents the target; yellow represents the pathway; blue represents disease.

Dissussion

Ulcerative colitis was first seen in “intestinal pi” in Neijing, with further records of “diarrhea, dysentery, and intestinal wind” in later generations. Its pathogenesis is based on spleen deficiency and loss of transport, marked by dampness-heat connotation and blood stasis, which runs through the whole process of the disease occurrence. Panax notoginseng can promote blood circulation to remove blood stasis and stop bleeding. It can treat “bright red blood under dysentery for a long time, intestinal rot, and ulcers”. Based on existing studies, we found that Panax notoginseng has a positive effect on ulcerative colitis, but its mechanism of action is still unclear. Network pharmacology studies the intervention and influence of drugs on diseases based on the interaction network of the herb-component-target-disease-KEGG pathway, which is a new method of studying the molecular mechanism of drugs and can comprehensively and systematically analyzing the relationship between drugs and diseases.

In this study, eight active components of Panax notoginseng were obtained by network pharmacological analysis, and the special component of Panax notoginseng “ginsenoside f2” was found. Through PPI analysis of intersection targets, it is speculated that STAT3, VEGFA, HSP90AA1, FGF2, IL2, MET, BCL2L1, and RORC are the key targets of ginsenoside f2 in the treatment of ulcerative colitis.

The STAT3 gene encodes a protein and is linked to diseases such as autosomal dominant hyper-IgE recurrent infection syndrome 1 and infantile-onset multisystem autoimmune disease.22 This gene is involved in several pathways, including IL-9 signaling and prolactin signaling.23 Gene Ontology annotations suggest that the protein coded by this gene possesses DNA-binding transcription factor activity and sequence-specific DNA binding capabilities.24 The VEGFA gene encodes a protein and is associated with diseases such as microvascular complications of diabetes 1 and POEMS syndrome.25 This gene is also involved in pathways related to the response to elevated platelet cytosolic calcium and the VEGF pathway, according to its related pathways.26 Gene Ontology annotations suggest that the protein encoded by this gene possesses the ability to both homodimerize and heterodimerize.25 The HSP90AA1 gene encodes a protein and is associated with diseases such as hepatocellular carcinoma and candidiasis. This gene is involved in pathways related to the resistance of ERBB2 KD mutants to osimertinib and the loss of Nlp from mitotic centrosomes.27 Gene Ontology annotations suggest that the protein encoded by this gene has RNA binding and identical protein binding capabilities.28 The FGF2 gene encodes a protein and is associated with diseases such as corneal neovascularization and chronic skin ulcers. This gene is involved in pathways related to downstream signaling of activated FGF2 and apoptotic pathways in synovial fibroblasts.29 Gene Ontology annotations suggest that the protein encoded by this gene has cytokine activity and heparin-binding capabilities.30 The IL2 gene encodes a protein and is associated with diseases such as breast cancer and smallpox. This gene is involved in pathways related to apoptotic pathways in synovial fibroblasts and MIF-mediated glucocorticoid regulation.31 Gene Ontology annotations suggest that the protein encoded by this gene has carbohydrate binding and growth factor activity capabilities.32 The MET gene encodes a protein and is associated with diseases such as renal cell carcinoma, papillary, deafness, and autosomal recessive. This gene is involved in pathways related to apoptotic pathways in synovial fibroblasts and the GPCR pathway.33 Gene Ontology annotations suggest that the protein encoded by this gene has transferase activity, transferring phosphorus-containing groups, and protein tyrosine kinase activity capabilities.34 The BCL2L1 gene encodes a protein and is associated with diseases such as absolute glaucoma and B-cell lymphoma. This gene is involved in pathways related to the RAF/MAP kinase cascade and death receptor signaling pathway. Gene Ontology annotations suggest that the protein encoded by this gene has protein homodimerization activity and protein heterodimerization activity capabilities.35,36 The RORC gene encodes a protein and is associated with diseases such as immunodeficiency and inflammatory bowel disease. This gene is involved in pathways related to gene expression (transcription) and cytokine production by Th17 cells in CF (Mouse model).37 Gene Ontology annotations suggest that the protein encoded by this gene has DNA-binding transcription factor activity and nuclear steroid receptor activity capabilities.38

KEGG enrichment analysis mainly involved EGFR tyrosine kinase inhibitor resistance, PI3K-Akt signaling pathway, proteoglycans in cancer, Th17 cell differentiation, inflammatory bowel disease, etc. The KEGG pathway, which is mainly associated with ulcerative colitis, was analyzed.

The PI3K-Akt signaling pathway is a signal transduction pathway that regulates a variety of biological processes, including cell growth, proliferation, survival, metabolism, and immune response.39 In immune responses, the PI3K-Akt signaling pathway is involved in immune response and immune tolerance by regulating the proliferation, survival, activation, and function of immune cells such as T cells, B cells, dendritic cells, and macrophages.40 The PI3K-Akt signaling pathway also plays an important role in ulcerative colitis. Several studies have shown that the PI3K-Akt signaling pathway is involved in the regulation of intestinal epithelial cell proliferation, survival, differentiation, and inflammatory response in the pathogenesis of ulcerative colitis.41 Specifically, the activation of the PI3K-Akt signaling pathway in intestinal epithelial cells can promote their proliferation and survival, as well as promote the infiltration of inflammatory cells and the production of inflammatory factors, thus exacerbating the degree of intestinal inflammation.39 In addition, the PI3K-Akt signaling pathway also plays an important role in the activation and function of intestinal immune cells.42 The PI3K-Akt signaling pathway can promote the proliferation, survival, and activation of immune cells such as T cells, B cells, and macrophages, thereby enhancing intestinal immune response and inflammatory response.42

IBD, which comprises Crohn’s disease (CD) and UC, is characterized by chronic inflammation of the gastrointestinal tract with various causes such as environmental and genetic factors, infectious microbes, and an imbalanced immune system.43 While numerous environmental factors such as geographic locations and smoking can contribute to the development of IBD, the luminal environment of the epithelial cells is believed to be the most crucial factor.44 Certain pathogens are more prevalent in individuals with IBD, and their microbial components, such as flagellin, peptidoglycan, and lipopolysaccharide, are recognized by receptors, including toll-like receptors (TLRs) and nucleotide-binding oligomerization domain (NOD) proteins, as well as antigen-presenting cells (APCs), in genetically susceptible hosts. TLR recognition activates NF-kappaB, which triggers an inflammatory response.43,45 The APC-expressed gene NOD2 has been linked to Crohn’s disease, and mutations in NOD2 result in reduced negative regulation of IL-12 production, leading to CD. Moreover, APCs are responsible for differentiating naive T cells into effector T cells (Th1, Th17, Th2) and natural killer T (NKT) cells. Th1 and Th17 cells produce high levels of IFN-gamma and IL-17, -22, respectively, both of which contribute to CD. On the other hand, Th2 cells produce IL-4, -5, and -10, which, together with IL-13 from NKT, induce UC.46,47

Conclusion

This study used network pharmacological methods to predict the special active ingredients, key targets, and action pathways of Panax notoginseng in the treatment of ulcerative colitis. It was found that the therapeutic mechanism of ginsenoside f2 for ulcerative colitis had multi-target and multi-pathway interactions. Studies have shown that the active component of ginsenoside f2 acts on key targets such as STAT3, VEGFA, HSP90AA1, FGF2, IL2, and MET. The GO enrichment analysis results involved 417 statistically significant pathways, among which 365 BP entries were statistically significant. It mainly involves positive chemotaxis, positive regulation of endothelial cell chemotaxis, regulation of endothelial cell chemotaxis, and T cell activation involved in immune response; there were 8 CC items with statistical significance, which mainly involved secretory granule lumen, cytoplasmic vesicle lumen, vesicle lumen, and lysosomal lumen. There were 44 MF entries with statistical significance mainly involving chemoattractant activity, growth factor receptor binding, protein phosphatase binding, growth factor activity, etc. KEGG enrichment analysis mainly involved EGFR tyrosine kinase inhibitor resistance, PI3K-Akt signaling pathway, proteoglycans in cancer, Th17 cell differentiation, inflammatory bowel disease, etc. The study provides a theoretical basis for further experimental research.

Abbreviations

BC: 

betweenness centrality

BP: 

Biological Process

CC: 

cellular component

CD: 

Crohn’s disease

DL: 

drug class

IBD: 

inflammatory bowel disease

MF: 

molecular function

NOD: 

nucleotide-binding oligomerization domain

OB: 

oral benefit

PPI: 

protein interaction network

TCM: 

traditional Chinese medicine

UC: 

ulcerative colitis

Declarations

Acknowledgement

None to declare.

Data sharing statement

The data used in support of the findings of this study are available from the corresponding author at weichensi14@outlook.com or weichens14@163.com upon request.

Funding

This study received no specific grant from any funding agency in the public, commercial, or not-for-profit sector.

Conflict of interest

The author has no conflict of interest related to this publication.

References

  1. Kucharzik T, Koletzko S, Kannengiesser K, Dignass A. Ulcerative Colitis-Diagnostic and Therapeutic Algorithms. Dtsch Arztebl Int 2020;117(33-34):564-574 View Article PubMed/NCBI
  2. Du L, Ha C. Epidemiology and Pathogenesis of Ulcerative Colitis. Gastroenterol Clin North Am 2020;49(4):643-654 View Article PubMed/NCBI
  3. Kaenkumchorn T, Wahbeh G. Ulcerative Colitis: Making the Diagnosis. Gastroenterol Clin North Am 2020;49(4):655-669 View Article PubMed/NCBI
  4. Keshteli AH, Madsen KL, Dieleman LA. Diet in the Pathogenesis and Management of Ulcerative Colitis; A Review of Randomized Controlled Dietary Interventions. Nutrients 2019;11(7):1498 View Article PubMed/NCBI
  5. Porter RJ, Kalla R, Ho GT. Ulcerative colitis: Recent advances in the understanding of disease pathogenesis. F1000Res 2020;9(F1000 Faculty Rev):294 View Article PubMed/NCBI
  6. Feuerstein JD, Moss AC, Farraye FA. Ulcerative Colitis. Mayo Clin Proc 2019;94(7):1357-1373 View Article PubMed/NCBI
  7. Lee SD. Health Maintenance in Ulcerative Colitis. Gastroenterol Clin North Am 2020;49(4):xv-xvi View Article PubMed/NCBI
  8. Burri E, Maillard MH, Schoepfer AM, Seibold F, Van Assche G, Rivière P, et al. Treatment Algorithm for Mild and Moderate-to-Severe Ulcerative Colitis: An Update. Digestion 2020;101(Suppl 1):2-15 View Article PubMed/NCBI
  9. Guo XY, Liu XJ, Hao JY. Gut microbiota in ulcerative colitis: insights on pathogenesis and treatment. J Dig Dis 2020;21(3):147-159 View Article PubMed/NCBI
  10. Roselli M, Finamore A. Use of Synbiotics for Ulcerative Colitis Treatment. Curr Clin Pharmacol 2020;15(3):174-182 View Article PubMed/NCBI
  11. Ru J, Li P, Wang J, Zhou W, Li B, Huang C, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J Cheminform 2014;6:13 View Article PubMed/NCBI
  12. Kim S, Chen J, Cheng T, Gindulyte A, He J, He S, et al. PubChem in 2021: new data content and improved web interfaces. Nucleic Acids Res 2021;49(D1):D1388-D1395 View Article PubMed/NCBI
  13. Daina A, Michielin O, Zoete V. SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Res 2019;47(W1):W357-W364 View Article PubMed/NCBI
  14. Stelzer G, Rosen N, Plaschkes I, Zimmerman S, Twik M, Fishilevich S, et al. The GeneCards suite: from gene data mining to disease genome sequence analyses. Curr Protoc Bioinformatics 2016;54:1.30.1-1.30.33 View Article PubMed/NCBI
  15. Amberger JS, Bocchini CA, Schiettecatte F, Scott AF, Hamosh A. OMIM.org: Online Mendelian Inheritance in Man (OMIM®), an online catalog of human genes and genetic disorders. Nucleic Acids Res 2015;43(Database issue):D789-D798 View Article PubMed/NCBI
  16. Piñero J, Ramírez-Anguita JM, Saüch-Pitarch J, Ronzano F, Centeno E, Sanz F, et al. The DisGeNET knowledge platform for disease genomics: 2019 update. Nucleic Acids Res 2020;48(D1):D845-D855 View Article PubMed/NCBI
  17. Oliveros JC. Venny: An interactive tool for comparing lists with Venn’s diagrams. 2007-2015. Available from: https://bioinfogp.cnb.csic.es/tools/venny/index.html
  18. Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res 2019;47(D1):D607-D613 View Article PubMed/NCBI
  19. Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 2012;16(5):284-287 View Article PubMed/NCBI
  20. Yu G, Wang LG, Yan GR, He QY. DOSE: an R/Bioconductor package for disease ontology semantic and enrichment analysis. Bioinformatics 2015;31(4):608-609 View Article PubMed/NCBI
  21. Luo W, Brouwer C. Pathview: an R/Bioconductor package for pathway-based data integration and visualization. Bioinformatics 2013;29(14):1830-1831 View Article PubMed/NCBI
  22. Zou S, Tong Q, Liu B, Huang W, Tian Y, Fu X. Targeting STAT3 in Cancer Immunotherapy. Mol Cancer 2020;19(1):145 View Article PubMed/NCBI
  23. Zhao J, Qi YF, Yu YR. STAT3: A key regulator in liver fibrosis. Ann Hepatol 2021;21:100224 View Article PubMed/NCBI
  24. Ouyang S, Li H, Lou L, Huang Q, Zhang Z, Mo J, et al. Inhibition of STAT3-ferroptosis negative regulatory axis suppresses tumor growth and alleviates chemoresistance in gastric cancer. Redox Biol 2022;52:102317 View Article PubMed/NCBI
  25. Zou G, Zhang X, Wang L, Li X, Xie T, Zhao J, et al. Herb-sourced emodin inhibits angiogenesis of breast cancer by targeting VEGFA transcription. Theranostics 2020;10(15):6839-6853 View Article PubMed/NCBI
  26. Liang L, Hui K, Hu C, Wen Y, Yang S, Zhu P, et al. Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells. J Exp Clin Cancer Res 2019;38(1):71 View Article PubMed/NCBI
  27. Liu H, Zhang Z, Huang Y, Wei W, Ning S, Li J, et al. Plasma HSP90AA1 Predicts the Risk of Breast Cancer Onset and Distant Metastasis. Front Cell Dev Biol 2021;9:639596 View Article PubMed/NCBI
  28. Shi W, Feng L, Dong S, Ning Z, Hua Y, Liu L, et al. FBXL6 governs c-MYC to promote hepatocellular carcinoma through ubiquitination and stabilization of HSP90AA1. Cell Commun Signal 2020;18(1):100 View Article PubMed/NCBI
  29. Du C, Davis JS, Chen C, Li Z, Cao Y, Sun H, et al. FGF2/FGFR signaling promotes cumulus-oocyte complex maturation in vitro. Reproduction 2021;161(2):205-214 View Article PubMed/NCBI
  30. Zhang J, Liu Z, Li Y, You Q, Yang J, Jin Y, et al. FGF2: a key regulator augmenting tendon-to-bone healing and cartilage repair. Regen Med 2020;15(9):2129-2142 View Article PubMed/NCBI
  31. Jung D, Shin S, Kang SM, Jung I, Ryu S, Noh S, et al. Reprogramming of T cell-derived small extracellular vesicles using IL2 surface engineering induces potent anti-cancer effects through miRNA delivery. J Extracell Vesicles 2022;11(12):e12287 View Article PubMed/NCBI
  32. Abbas AK, Trotta E, R Simeonov D, Marson A, Bluestone JA. Revisiting IL-2: Biology and therapeutic prospects. Sci Immunol 2018;3(25):eaat1482 View Article PubMed/NCBI
  33. Yang X, Liao HY, Zhang HH. Roles of MET in human cancer. Clin Chim Acta 2022;525:69-83 View Article PubMed/NCBI
  34. Dong Y, Xu J, Sun B, Wang J, Wang Z. MET-Targeted Therapies and Clinical Outcomes: A Systematic Literature Review. Mol Diagn Ther 2022;26(2):203-227 View Article PubMed/NCBI
  35. Warren CFA, Wong-Brown MW, Bowden NA. BCL-2 family isoforms in apoptosis and cancer. Cell Death Dis 2019;10(3):177 View Article PubMed/NCBI
  36. Xu J, Guo Z, Yuan S, Li H. BCL2L1 is identified as a target of naringenin in regulating ovarian cancer progression. Mol Cell Biochem 2022;477(5):1541-1553 View Article PubMed/NCBI
  37. Cornelissen F, Aparicio Domingo P, Reijmers RM, Cupedo T. Activation and effector functions of human RORC+ innate lymphoid cells. Curr Opin Immunol 2011;23(3):361-367 View Article PubMed/NCBI
  38. Michelini S, Ricci M, Serrani R, Stuppia L, Beccari T, Veselenyiova D, et al. Possible Role of the RORC Gene in Primary and Secondary Lymphedema: Review of the Literature and Genetic Study of Two Rare Causative Variants. Lymphat Res Biol 2021;19(2):129-133 View Article PubMed/NCBI
  39. Xu W, Yang Z, Lu N. A new role for the PI3K/Akt signaling pathway in the epithelial-mesenchymal transition. Cell Adh Migr 2015;9(4):317-324 View Article PubMed/NCBI
  40. Guo X, Sun W, Luo G, Wu L, Xu G, Hou D, et al. Panax notoginseng saponins alleviate skeletal muscle insulin resistance by regulating the IRS1-PI3K-AKT signaling pathway and GLUT4 expression. FEBS Open Bio 2019;9(5):1008-1019 View Article PubMed/NCBI
  41. Asati V, Mahapatra DK, Bharti SK. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives. Eur J Med Chem 2016;109:314-341 View Article PubMed/NCBI
  42. Sharma A, Mehan S. Targeting PI3K-AKT/mTOR signaling in the prevention of autism. Neurochem Int 2021;147:105067 View Article PubMed/NCBI
  43. Chen X, Liu G, Yuan Y, Wu G, Wang S, Yuan L. NEK7 interacts with NLRP3 to modulate the pyroptosis in inflammatory bowel disease via NF-κB signaling. Cell Death Dis 2019;10(12):906 View Article PubMed/NCBI
  44. Lu Y, Li X, Liu S, Zhang Y, Zhang D. Toll-like Receptors and Inflammatory Bowel Disease. Front Immunol 2018;9:72 View Article PubMed/NCBI
  45. Wallace KL, Zheng LB, Kanazawa Y, Shih DQ. Immunopathology of inflammatory bowel disease. World J Gastroenterol 2014;20(1):6-21 View Article PubMed/NCBI
  46. Yan JB, Luo MM, Chen ZY, He BH. The Function and Role of the Th17/Treg Cell Balance in Inflammatory Bowel Disease. J Immunol Res 2020;2020:8813558 View Article PubMed/NCBI
  47. Xie Z, Wang Y, Yang G, Han J, Zhu L, Li L, et al. The role of the Hippo pathway in the pathogenesis of inflammatory bowel disease. Cell Death Dis 2021;12(1):79 View Article PubMed/NCBI
Copyright © 2023 Authors. This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 4.0 License (CC BY-NC 4.0), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

About this Article

Cite this article
Si W. Exploring the Modern Pharmacological Mechanism of Special Ingredients of Panax Ginseng for Ulcerative Colitis based on Network Pharmacology. Future Integrative Medicine. 2023;2(2):90-98. doi: 10.14218/FIM.2022.00058.
Copy        Export to RIS        Export to EndNote
Article History
Received Revised Accepted Published
February 22, 2023 April 3, 2023 June 6, 2023 June 25, 2023
DOI http://dx.doi.org/10.14218/FIM.2022.00058
  • Future Integrative Medicine
  • pISSN 2993-5253
  • eISSN 2835-6357
  • © 2025 Xia & He Publishing Inc.
  • Total visits : 3331825
  • Visits today : 5766
Back to Top

Exploring the Modern Pharmacological Mechanism of Special Ingredients of Panax Ginseng for Ulcerative Colitis based on Network Pharmacology

Weichen Si
  • Reset Zoom
  • Download TIFF